TRACON Pharmaceuticals (NASDAQ:TCON) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a research report released on Monday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating on shares of TRACON Pharmaceuticals in a research note on Monday, July 1st.

TRACON Pharmaceuticals Stock Performance

NASDAQ:TCON opened at $0.08 on Monday. The stock has a market capitalization of $273,142.00, a PE ratio of 0.12 and a beta of 1.36. TRACON Pharmaceuticals has a 1-year low of $0.00 and a 1-year high of $14.75. The firm has a fifty day simple moving average of $0.10 and a 200 day simple moving average of $0.76.

TRACON Pharmaceuticals (NASDAQ:TCON) last announced its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.94) EPS for the quarter. The firm had revenue of $0.06 million for the quarter.

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.